Neonatal Hypoglycaemia

1. Clinical Overview

Summary

Neonatal hypoglycaemia is the most common metabolic disturbance in the newborn period, affecting up to 15% of all newborns and up to 50% of at-risk infants. [1] Glucose is the primary substrate for cerebral metabolism in neonates, with the neonatal brain consuming approximately 90% of whole-body glucose utilization. [2] Prolonged or severe hypoglycaemia can cause neuronal necrosis and permanent neurodevelopmental impairment, including occipital lobe injury, cerebral palsy, and cognitive deficits. [3,4]

The operational threshold for intervention varies between international guidelines, but the British Association of Perinatal Medicine (BAPM 2017) defines the intervention threshold as less than 2.6 mmol/L (47 mg/dL) in at-risk infants after the first two hours of life. [5] However, lower glucose concentrations are physiologically normal in the first few hours after birth during the transitional period, often referred to as "transitional hypoglycaemia," with values occasionally dropping to 1.0-1.5 mmol/L without adverse consequences in healthy term infants. [6]

The challenge in neonatal hypoglycaemia management lies in distinguishing between physiological adaptation (which requires no intervention beyond feeding) and pathological hypoglycaemia (which requires urgent treatment to prevent brain injury). The cornerstone of management is early identification through targeted screening of at-risk infants, prompt treatment with feeding and/or dextrose gel, and escalation to intravenous dextrose when conservative measures fail. [7]

Clinical Pearls

The "Jittery" Baby: Jitteriness (tremor) is the classic sign of neonatal hypoglycaemia. To distinguish it from a seizure:

• Jitteriness: Stimulus-sensitive, stops when you hold or restrain the limb, no eye deviation or autonomic features.
• Seizure: Continues despite holding (clonic movement), accompanied by eye deviation, apnoea, or autonomic instability.

Asymptomatic is Common: Approximately 50-70% of hypoglycaemic neonates are asymptomatic. [8] This is why we screen "At Risk" groups (preterm, small for gestational age, infant of diabetic mother) routinely, regardless of symptoms. The absence of symptoms does not equate to safety—asymptomatic hypoglycaemia is associated with neurodevelopmental impairment. [9]

Hyperinsulinism Trap: Neonates who require very high glucose infusion rates (> 10-12 mg/kg/min) to maintain normoglycaemia almost certainly have hyperinsulinism (e.g., congenital hyperinsulinism, Beckwith-Wiedemann syndrome, or infant of diabetic mother with persistent hyperinsulinism). They need specific treatment with diazoxide or octreotide, not just increasing dextrose concentration. [10]

The "Critical Sample": If hypoglycaemia persists beyond 48 hours or is severe/recurrent, obtain the "hypoglycaemia screen" during an episode before treatment. This includes insulin, C-peptide, ketones, cortisol, growth hormone, lactate, and free fatty acids. This single blood sample can differentiate between hyperinsulinism, hormonal deficiencies, and inborn errors of metabolism. [11]

Dextrose Gel Revolution: The SugarBabies trial transformed neonatal hypoglycaemia management by demonstrating that 40% dextrose gel (200 mg/kg) massaged into the buccal mucosa is as effective as intravenous dextrose for mild-moderate hypoglycaemia, reduces NICU admissions by 50%, and is now first-line treatment in many centers. [12]

---

2. Epidemiology

Incidence and Prevalence

The incidence of neonatal hypoglycaemia varies dramatically depending on the population studied, definition used, and screening protocols employed:

• General population: 5-15% of all newborns experience at least one episode of blood glucose less than 2.6 mmol/L in the first 48 hours. [1]
• At-risk populations: 30-50% of at-risk infants (preterm, SGA, IDM, LGA) develop hypoglycaemia. [13]
• Severe hypoglycaemia (less than 1.0 mmol/L): Occurs in approximately 0.5-1% of all births. [14]
• Persistent/recurrent hypoglycaemia: Affects 1-5 per 100,000 live births and suggests underlying pathology. [15]

Risk Factor Groups: The Pathophysiological Triad

Neonatal hypoglycaemia arises from three fundamental mechanisms: increased glucose consumption, decreased glucose production, or a combination of both. [16]

1. Increased Glucose Consumption (Hyperinsulinaemic States)

Hyperinsulinism is the most common cause of persistent, severe, and recurrent neonatal hypoglycaemia requiring high glucose infusion rates.

Infant of Diabetic Mother (IDM)

• Mechanism: Maternal hyperglycaemia leads to fetal hyperglycaemia → fetal pancreatic β-cell hyperplasia → neonatal hyperinsulinism persisting for 24-72 hours post-delivery. [17]
• Incidence: Up to 40% of IDMs develop hypoglycaemia in the first 24 hours. [18]
• Severity: Generally resolves within 48-72 hours as insulin levels normalize.

Large for Gestational Age (LGA)

• Definition: Birth weight > 90th centile for gestational age.
• Risk: 15-25% develop hypoglycaemia, often due to relative hyperinsulinism. [19]

Beckwith-Wiedemann Syndrome (BWS)

• Features: Macroglossia, macrosomia, omphalocele, hemihypertrophy, ear creases/pits.
• Mechanism: Pancreatic β-cell hyperplasia (in 50% of cases), leading to severe, persistent hyperinsulinaemic hypoglycaemia. [20]
• Management: Often requires diazoxide or even pancreatectomy.

Congenital Hyperinsulinism (CHI)

• Incidence: 1 in 30,000-50,000 live births (higher in consanguineous populations).
• Genetics: Mutations in ABCC8, KCNJ11 (K-ATP channel defects), GCK, GLUD1, HNF4A, and others. [21]
• Presentation: Severe, persistent hypoglycaemia requiring glucose infusion rates > 10-15 mg/kg/min.

2. Decreased Glucose Production (Depleted Glycogen/Gluconeogenesis Substrate)

These infants have inadequate glycogen stores or impaired gluconeogenesis, preventing the normal metabolic adaptation to extrauterine life.

Intrauterine Growth Restriction (IUGR) / Small for Gestational Age (SGA)

• Definition: Birth weight less than 10th centile (severe SGA less than 2nd centile).
• Mechanism: Chronic placental insufficiency → reduced glycogen deposition in liver and muscle during third trimester → depleted stores at birth. [22]
• Incidence: 30-50% of SGA infants develop hypoglycaemia. [23]
• Key difference: Ketone production is typically preserved (unlike hyperinsulinism).

Preterm Infants (less than 37 weeks)

• Mechanism:
  • Glycogen stores are primarily laid down in the third trimester. Preterm infants miss this critical window.
  • Immature gluconeogenesis and ketogenesis pathways.
  • Higher metabolic rate relative to stores. [24]
• Incidence: 10-15% of preterm infants less than 35 weeks develop hypoglycaemia. [25]

3. Increased Consumption (Metabolic Stress)

Perinatal Asphyxia / Hypoxic-Ischaemic Encephalopathy (HIE)

• Mechanism: Tissue hypoxia → anaerobic glycolysis → rapid glucose depletion, compounded by impaired gluconeogenesis due to hepatic dysfunction. [26]
• Management challenge: Hypoglycaemia worsens brain injury; hyperglycaemia (overshoot during treatment) may also be harmful. [27]

Neonatal Sepsis

• Mechanism: Systemic inflammatory response → increased glucose utilization, impaired hepatic glucose production, and sometimes adrenal insufficiency. [28]
• Clinical clue: Hypoglycaemia in a previously stable infant should raise suspicion of sepsis.

Hypothermia

• Mechanism: Non-shivering thermogenesis via brown adipose tissue utilizes glucose and free fatty acids. Cold stress dramatically increases glucose consumption. [29]
• Prevention: "Warm and Feed" is the mantra—hypothermia prevention is hypoglycaemia prevention.

Polycythaemia (Haematocrit > 65%)

• Mechanism: Increased red cell mass → increased glucose consumption by red blood cells. [30]
• Association: Often seen in IUGR, post-term infants, twin-twin transfusion recipients.

Inborn Errors of Metabolism (Rare but Critical)

• Glycogen Storage Diseases (Type I, III, IV): Impaired glycogenolysis.
• Fatty Acid Oxidation Defects (MCAD, LCAD, VLCAD): Impaired ketogenesis, hypoketotic hypoglycaemia.
• Galactosaemia, Hereditary Fructose Intolerance: Acquired hepatic dysfunction.
• Presentation: Persistent hypoglycaemia beyond 7 days, failure to respond to standard treatment. [31]

Endocrine Causes (Rare)

• Hypopituitarism: Growth hormone and ACTH deficiency → impaired gluconeogenesis and counter-regulation.
  • "Clues: Midline defects (cleft palate, single central incisor), micropenis, prolonged jaundice."
• Congenital Adrenal Hyperplasia: Cortisol deficiency.
• Hypothyroidism: Rarely causes hypoglycaemia but may contribute. [32]

Maternal Risk Factors

• Maternal diabetes (Type 1, Type 2, Gestational): Strongest maternal risk factor.
• Beta-blocker or oral hypoglycaemic use: Can cross placenta and cause neonatal hypoglycaemia.
• Terbutaline/salbutamol (tocolytics): Stimulate fetal insulin secretion. [33]
• Maternal intrapartum dextrose infusion: Can cause fetal hyperglycaemia → reactive neonatal hypoglycaemia. [34]

---

3. Pathophysiology

Fetal-to-Neonatal Metabolic Transition

Understanding neonatal hypoglycaemia requires understanding the profound metabolic shift that occurs at birth. [35]

In Utero (Fetal Metabolism)

• Continuous glucose supply: Fetus receives constant glucose via facilitated diffusion across the placenta (GLUT1 transporters).
• Fetal glucose concentration: Approximately 70-80% of maternal levels (e.g., maternal 4.5 mmol/L → fetal 3.5 mmol/L).
• Insulin dominant: Fetal insulin promotes growth (anabolic state).
• Minimal gluconeogenesis: Fetal liver is immature; gluconeogenesis is suppressed.
• Glycogen deposition: Third trimester is critical for hepatic and muscle glycogen accumulation. [36]

At Birth (Cord Clamping)

• Abrupt cessation of glucose supply: Placental supply is cut.
• Glucose nadir: Blood glucose falls to a physiological nadir of 1.0-2.5 mmol/L at 1-2 hours of life in healthy term infants. [6]
• Counter-regulatory surge:
  • "Glucagon: Rises 3-5 fold within minutes → stimulates glycogenolysis."
  • "Catecholamines (epinephrine, norepinephrine): Surge during delivery → stimulate glycogenolysis and lipolysis."
  • "Cortisol: Rises → stimulates gluconeogenesis."
  • "Growth hormone: Supports gluconeogenesis. [37]"

First 24-48 Hours (Metabolic Adaptation)

• Glycogenolysis: Hepatic glycogen stores (approximately 60 g in term infant) are mobilized, providing glucose for 8-12 hours.
• Gluconeogenesis: Activated within 4-6 hours, utilizing lactate, alanine, and glycerol substrates.
• Ketogenesis: Brown adipose tissue lipolysis → free fatty acids → hepatic ketone body production (β-hydroxybutyrate, acetoacetate), providing alternative fuel for brain. [38]
• Feeding establishes: Breast milk/formula provides exogenous glucose and substrates.
• Glucose stabilizes: By 48-72 hours, glucose typically stabilizes at 3.0-5.0 mmol/L between feeds.

Why At-Risk Infants Fail to Adapt

Hyperinsulinaemic Infants (IDM, CHI, BWS)

• Insulin excess suppresses:
  • Glycogenolysis
  • Gluconeogenesis
  • "Ketogenesis (pathognomonic: hypoketotic hypoglycaemia)"
  • Lipolysis
• Result: Severe, persistent hypoglycaemia with inappropriately suppressed ketones and free fatty acids. [10]

SGA/IUGR Infants

• Depleted glycogen stores: Chronic malnutrition in utero prevents glycogen accumulation.
• Limited fat stores: Reduced substrate for ketogenesis.
• Higher brain:body mass ratio: Disproportionate glucose consumption by brain.
• Result: Early hypoglycaemia (first 6-12 hours) as glycogen stores are exhausted, but ketogenesis is typically preserved. [22]

Preterm Infants

• Immature enzyme systems: Gluconeogenesis pathways (PEPCK, G6Pase) are incompletely developed.
• Missed glycogen window: Glycogen deposition occurs primarily after 36 weeks.
• High metabolic rate: Greater glucose consumption per kg.
• Result: Both impaired production and increased consumption. [24]

Cerebral Glucose Metabolism and Injury Mechanisms

The neonatal brain is critically dependent on glucose, consuming 4-6 mg/kg/min (compared to 2-3 mg/kg/min in adults). [2]

Mechanisms of Hypoglycaemic Brain Injury:

1. Direct neurotoxicity: Glucose deprivation → ATP depletion → neuronal necrosis (especially occipital cortex, parietal cortex, hippocampus). [39]
2. Excitotoxicity: Hypoglycaemia triggers glutamate release → NMDA receptor activation → calcium influx → apoptosis. [40]
3. Regional vulnerability: Occipital lobes are most vulnerable (explaining cortical blindness in severe cases).
4. Threshold and duration: Risk is determined by both severity (less than 1.0 mmol/L) and duration (> 3 hours associated with injury). [3,4]

Neuroprotective adaptations:

• Ketone utilization: Neonatal brain can utilize ketones (β-hydroxybutyrate) as alternative fuel, providing partial protection during hypoglycaemia. [38]
• Lower glucose threshold: Neonatal neurons may tolerate lower glucose concentrations than adult neurons (hence physiological transitional hypoglycaemia is safe in healthy infants).

---

4. Clinical Presentation

Symptoms and Signs

The clinical presentation of neonatal hypoglycaemia is highly variable, ranging from completely asymptomatic (most common) to life-threatening seizures and coma. [8]

Neuroglycopenic Signs (CNS Glucose Deprivation)

• Jitteriness/tremors: Most common sign, present in 30-40% of symptomatic hypoglycaemia.
• Irritability or high-pitched cry
• Hypotonia ("floppy baby")
• Lethargy, poor feeding, weak suck
• Seizures: Generalized or focal clonic movements (occurs in severe hypoglycaemia less than 1.0 mmol/L).
• Apnoea: May be the only sign, particularly in preterm infants.
• Coma: Rare, indicates severe prolonged hypoglycaemia. [41]

Autonomic/Adrenergic Signs (Catecholamine Response)

• Pallor
• Sweating: Rare in neonates due to immature sweat glands.
• Tachycardia
• Cyanosis: Suggests cardiorespiratory compromise.
• Temperature instability: Hypothermia or hyperthermia. [42]

Asymptomatic Hypoglycaemia

• Incidence: 50-70% of hypoglycaemic episodes are asymptomatic. [8]
• Clinical significance: Asymptomatic hypoglycaemia is NOT benign. The CHYLD study demonstrated that even asymptomatic hypoglycaemia less than 2.6 mmol/L is associated with reduced executive function and visual-motor skills at age 2 and 4.5 years. [9,43]
• Implication: Screening at-risk infants is essential regardless of symptoms.

Timing and Duration

Transient Hypoglycaemia

• Definition: Resolves within 7 days of life.
• Causes: IDM, SGA, prematurity, perinatal stress.
• Natural history: Typically resolves as feeding is established and metabolic adaptation completes.

Persistent Hypoglycaemia

• Definition: Hypoglycaemia lasting > 7 days.
• Causes:
  • Congenital hyperinsulinism
  • Hypopituitarism
  • Inborn errors of metabolism
  • Beckwith-Wiedemann syndrome
• Red flag: Any hypoglycaemia persisting beyond the first week requires urgent investigation for underlying pathology. [11]

Recurrent Hypoglycaemia

• Definition: Multiple episodes despite treatment.
• Causes: Similar to persistent hypoglycaemia.
• Action: Obtain critical sample (hypoglycaemia screen) and refer to endocrinology/metabolics.

---

5. Clinical Examination

General Inspection

Size and Growth Parameters

• Macrosomia (> 4 kg or > 90th centile): Suggests IDM or Beckwith-Wiedemann syndrome.
• Wasting/emaciation (low weight for length): Suggests IUGR.
• Length and head circumference: Symmetrical vs asymmetrical growth restriction.

Respiratory Examination

• Respiratory distress: May indicate sepsis, pneumonia, or polycythaemia causing hypoglycaemia.
• Apnoea: Direct sign of neuroglycopenia.

Dysmorphology Assessment

Beckwith-Wiedemann Syndrome Features

• Macroglossia (large tongue protruding from mouth)
• Omphalocele or umbilical hernia
• Ear creases or ear pits (helical pits)
• Hemihypertrophy (asymmetrical limb growth)
• Visceromegaly: Hepatomegaly, nephromegaly. [20]

Hypopituitarism Features

• Midline defects: Cleft lip/palate, single central incisor
• Micropenis (less than 2 cm stretched length in term male)
• Undescended testes
• Prolonged conjugated jaundice (combined GH and TSH deficiency). [32]

Other Syndromic Features

• Trisomy 13, 18: Severe IUGR, dysmorphic features.
• Patau syndrome: Holoprosencephaly, may have hypopituitarism.

Neurological Examination

Level of Consciousness

• Alert, responsive to handling: Normal.
• Lethargic: Reduced spontaneous movement, requires stimulation to wake.
• Stuporose/comatose: Unresponsive (severe hypoglycaemia).

Tone Assessment

• Hypotonia: "Floppy," reduced resistance to passive movement.
• Hypertonia: May occur after seizure or with severe encephalopathy.

Primitive Reflexes

• Moro reflex, rooting, sucking, grasp: Should be present; absence suggests neurological depression.

Seizure Activity

• Subtle seizures: Eye deviation, cycling movements, apnoea.
• Clonic seizures: Rhythmic jerking of limbs that persists despite restraint.
• Tonic seizures: Stiffening/extension. [41]

Cardiovascular and Abdominal Examination

• Cyanosis: Suggests cardiorespiratory instability.
• Hepatomegaly: Seen in glycogen storage diseases, CHI (some subtypes), or congestive cardiac failure.
• Abdominal masses: Wilms tumor, neuroblastoma (paraneoplastic hyperinsulinism is rare but described). [44]

---

6. Investigations

Screening and Monitoring

Heel Prick (Point-of-Care) Glucose Monitoring

• Method: Capillary blood glucose using glucometer.
• Timing:
  • "At-risk infants: First measurement at 2-4 hours of age (after initial feed), then every 3-4 hours before feeds until stable (≥2.6 mmol/L for 2 consecutive feeds)."
  • "Symptomatic infants: Immediate measurement. [5,7]"
• Limitations:
  • Glucometers are inaccurate at low glucose levels (may underestimate by 0.5-1.0 mmol/L).
  • False low readings with polycythaemia (red cells consume glucose ex vivo).
• Threshold for action: less than 2.6 mmol/L requires intervention and confirmatory laboratory sample.

Laboratory Glucose Confirmation

• Indication: All heel prick values less than 2.6 mmol/L should be confirmed with laboratory plasma glucose (venous or arterial blood gas).
• Method: Venous/arterial sample sent to laboratory in fluoride-oxalate tube (prevents glycolysis).
• Critical: Do NOT delay treatment while waiting for laboratory confirmation if infant is symptomatic. [45]

The "Hypoglycaemia Screen" (Critical Sample)

When hypoglycaemia is persistent (> 48 hours), recurrent, severe (less than 1.5 mmol/L), or requires high glucose infusion rates (> 8 mg/kg/min), obtain a critical sample during hypoglycaemia before administering dextrose. [11]

Timing: Sample must be taken when glucose is less than 2.6 mmol/L (ideally less than 2.0 mmol/L) to maximize diagnostic yield.

Essential Investigations:

Interpretation Patterns:

• Hyperinsulinism: ↑ Insulin, ↑ C-peptide, ↓ Ketones, ↓ FFA, normal lactate.
• Hypopituitarism: ↓ GH, ↓ Cortisol, ↑ Ketones (appropriate), normal insulin.
• Fatty acid oxidation defect: ↓ Ketones (inappropriate), ↑ Acylcarnitines, normal insulin.
• Glycogen storage disease: ↑ Lactate, ↑ Uric acid, hepatomegaly. [46]

Additional Investigations

Genetic Testing

• Indication: Suspected congenital hyperinsulinism, Beckwith-Wiedemann syndrome, or glycogen storage disease.
• Genes: ABCC8, KCNJ11, GCK, GLUD1, HNF4A (CHI); 11p15 methylation defect (BWS). [21]

Imaging

• Brain MRI: If seizures or concern for hypoglycaemic brain injury (occipital lobe changes). [47]
• 18F-DOPA PET scan: Gold standard for differentiating focal vs diffuse congenital hyperinsulinism (guides surgical management). [48]
• Abdominal ultrasound: Assess for Beckwith-Wiedemann features (nephromegaly, organomegaly, Wilms tumor surveillance).

Endocrine Function Tests

• Thyroid function (TSH, free T4): Rule out hypothyroidism.
• IGF-1, IGFBP-3: Markers of growth hormone status.
• ACTH stimulation test: If suspected adrenal insufficiency.
• Glucagon stimulation test: Assesses glycogen stores and insulin response (rise in glucose > 1.5 mmol/L suggests adequate stores; insulin rise suggests hyperinsulinism). [32]

---

7. Management

Principles of Management

1. Prevention: Keep warm, early feeding, identify at-risk infants.
2. Early detection: Targeted screening of at-risk groups.
3. Prompt treatment: Avoid prolonged hypoglycaemia.
4. Escalation pathway: Feed → Dextrose gel → IV dextrose → Medications.
5. Investigate persistent/severe cases: Obtain critical sample, involve specialists. [5,7]

Management Algorithm (BAPM 2017 Framework)

           NEONATAL HYPOGLYCAEMIA SUSPECTED
                       ↓
              MEASURE BLOOD GLUCOSE
                       ↓
         ┌─────────────┴─────────────┐
    SYMPTOMATIC?                ASYMPTOMATIC
  (Seizures, Apnoea,              BUT less than 2.6?
   Lethargy, Jittery)                ↓
         ↓                      AT-RISK INFANT?
   ADMIT NICU                  (IDM, SGA, Preterm)
   IV DEXTROSE                        ↓
   Bolus 200 mg/kg             FEED + KEEP WARM
   (2 mL/kg 10%)              (Breast or formula)
         ↓                            ↓
   Start maintenance          Recheck in 30 minutes
   Dextrose 10%                       ↓
   60-80 mL/kg/day            STILL less than 2.6 mmol/L?
         ↓                      ┌─────┴─────┐
   Monitor q1-2h              YES          NO
         ↓                      ↓            ↓
   Adjust GIR to        BUCCAL DEXTROSE  CONTINUE
   maintain > 2.6         GEL 40%        FEEDS
         ↓               200 mg/kg       Monitor
   Screen for cause     + FEED           q3-4h
         ↓                      ↓
   Persistent?          Recheck 30 min
   > 48h or GIR > 8              ↓
         ↓              STILL less than 2.6?
   CRITICAL SAMPLE             ↓
   Endocrine review       ADMIT NICU
                         IV DEXTROSE

Step-by-Step Management

Step 1: Prevention (All Neonates)

• Keep warm: Prevent hypothermia (target axillary temperature 36.5-37.5°C). Use skin-to-skin care, radiant warmer as needed.
• Early feeding: Initiate breastfeeding or formula within 1 hour of birth in all infants.
• Identify at-risk infants: IDM, SGA, LGA, preterm, perinatal asphyxia, maternal medication (beta-blockers, sulfonylureas). [29]

Step 2: Screening (At-Risk Infants)

• First measurement: 2-4 hours after birth (after first feed).
• Subsequent measurements: Pre-feed (every 3-4 hours) until 2 consecutive readings ≥2.6 mmol/L.
• Target: Blood glucose ≥2.6 mmol/L after first 2-4 hours of life. [5]

Step 3: First-Line Treatment (Asymptomatic, Glucose 1.5-2.6 mmol/L)

A. Increase Feeding Frequency

• Breast or formula feed: Increase frequency to 2-3 hourly.
• Volume: Ensure adequate intake (50-60 mL/kg/day on Day 1, increasing).
• Recheck: 30-60 minutes after feed. [7]

B. Buccal Dextrose Gel (40%)

• Evidence: SugarBabies trial (2013) showed 40% dextrose gel reduced NICU admissions by 50% and was as effective as IV dextrose for mild-moderate hypoglycaemia. [12]
• Dose: 200 mg/kg (0.5 mL/kg of 40% gel).
• Method: Massage into buccal mucosa (inside cheek). Absorption is rapid (onset 10-15 minutes).
• Repeat: Can repeat once after 30 minutes if glucose remains less than 2.6 mmol/L.
• Follow with feed: Always give oral feed immediately after gel. [49]
• Contraindication: Nil by mouth status, impaired swallow, severe hypoglycaemia (less than 1.0 mmol/L).

Step 4: Second-Line Treatment (Symptomatic or Glucose less than 1.5 mmol/L or Failure of First-Line)

Intravenous Dextrose

A. Bolus (if Symptomatic/Severe less than 1.0 mmol/L or Seizing)

• Dose: 200 mg/kg (2 mL/kg of 10% dextrose).
• Route: IV or intraosseous (if no IV access).
• Method: Give over 5 minutes (NOT rapid push—risk of rebound hypoglycaemia from insulin surge).
• NEVER use 50% dextrose in neonates: Risk of sclerosis, skin necrosis, and osmotic injury. [45]

B. Maintenance Infusion

• Initial GIR (Glucose Infusion Rate): 4-6 mg/kg/min.
  • "Calculation: GIR (mg/kg/min) = [Dextrose % × Infusion rate (mL/h)] ÷ [6 × Weight (kg)]"
  • "Example: 10% dextrose at 3 mL/h in a 3 kg infant = (10 × 3) ÷ (6 × 3) = 1.67 mg/kg/min"
• Standard maintenance: 60-80 mL/kg/day of 10% dextrose = ~4-6 mg/kg/min GIR.
• Monitoring: Check glucose every 1-2 hours initially, then every 3-4 hours once stable.
• Target: Glucose 2.6-6.0 mmol/L (avoid hyperglycaemia). [50]

C. Escalation of GIR

• Increase by 1-2 mg/kg/min if glucose remains less than 2.6 mmol/L.
• Maximum GIR via peripheral line: ~12.5% dextrose (risk of extravasation injury at higher concentrations).
• If GIR > 8-10 mg/kg/min required: Suspect hyperinsulinism; consider:
  • Central line for higher dextrose concentrations (15%, 20%).
  • Pharmacological treatment (diazoxide, octreotide).
  • Critical sample before escalation. [11]

Step 5: Third-Line Treatment (Persistent/Refractory Hypoglycaemia)

Pharmacological Agents

A. Glucagon

• Mechanism: Stimulates hepatic glycogenolysis (mobilizes glycogen stores).
• Dose: 0.1-0.3 mg/kg IM/IV (maximum 1 mg).
• Indication: Temporary measure for severe hypoglycaemia when IV access is not immediately available, or as a bridge to IV dextrose.
• Limitation: Ineffective in SGA/IUGR (depleted glycogen stores), ineffective in glycogen storage diseases, short-acting (30-60 minutes). [51]

B. Diazoxide

• Mechanism: Opens K-ATP channels in pancreatic β-cells → inhibits insulin secretion.
• Indication: First-line for hyperinsulinaemic hypoglycaemia (CHI, BWS, persistent IDM).
• Dose: 5-15 mg/kg/day divided TDS orally.
• Response: 50-60% of CHI cases respond to diazoxide (K-ATP channel responsive forms). [52]
• Side effects: Fluid retention (give with chlorothiazide), hypertrichosis, hyperuricaemia.
• Monitoring: FBC (neutropenia rare), uric acid.

C. Octreotide

• Mechanism: Somatostatin analogue → inhibits insulin secretion.
• Indication: Diazoxide-unresponsive hyperinsulinism (K-ATP channel defects).
• Dose: 5-25 mcg/kg/day SC/IV divided QDS.
• Side effects: Tachyphylaxis, necrotizing enterocolitis (rare but serious), gallstones (chronic use). [53]
• Monitoring: Close observation for feeding intolerance, abdominal distension.

D. Hydrocortisone

• Mechanism: Promotes gluconeogenesis, counter-regulatory hormone.
• Indication: Suspected adrenal insufficiency or hypopituitarism.
• Dose: 2.5-5 mg/kg/day IV/PO divided BDS.
• Role in hyperinsulinism: Sometimes used as adjunct but limited evidence. [54]

E. Nifedipine

• Mechanism: Calcium channel blocker → inhibits insulin secretion.
• Indication: Experimental use in diazoxide/octreotide-resistant cases.
• Dose: 0.5-2.5 mg/kg/day.
• Evidence: Limited; case reports only. [55]

Step 6: Surgical Management (Focal Hyperinsulinism)

Indication: Diazoxide-unresponsive congenital hyperinsulinism with focal lesion on 18F-DOPA PET scan.

• Procedure: Partial pancreatectomy (excision of focal adenomatous hyperplasia).
• Outcome: Curative in focal disease (90-95% cure rate if lesion completely excised). [48]
• Diffuse disease: Near-total pancreatectomy (95-98% resection) may be required but carries high risk of diabetes mellitus.

Weaning and Discontinuation

Once glucose is stable (> 2.6 mmol/L consistently):

1. Establish enteral feeding: Transition from IV to oral feeds (breast/formula).
2. Gradual weaning: Reduce GIR by 1-2 mg/kg/min every 6-12 hours, monitoring glucose before and after reduction.
3. Maintain feeding: Ensure adequate oral intake as IV support decreases.
4. Pre-discharge screening: Check glucose before discharge (at least 6-8 hours after last IV dextrose stopped, pre-feed). [7]

Special Scenarios

Infant of Diabetic Mother (IDM)

• Anticipated hypoglycaemia: Screen at 2 hours, then 3-4 hourly for 24 hours.
• Usually transient: Resolves by 48-72 hours as insulin levels normalize.
• Persistent hypoglycaemia (> 48h): Consider critical sample—may indicate BWS or CHI (especially if maternal diabetes is gestational and poorly controlled). [18]

Small for Gestational Age (SGA)

• Early screening: First 12-24 hours critical (glycogen depletion).
• Feeding strategy: Frequent feeds (2-3 hourly).
• Low threshold for IV dextrose: SGA infants often need IV support in first 24h. [23]

Preterm Infants

• Lower threshold for intervention: Some advocate for less than 2.0 mmol/L in first 24h, then less than 2.6 mmol/L.
• IV dextrose often required: Many preterm less than 35 weeks need IV glucose initially.
• Monitor for hyperglycaemia: Preterm infants have impaired insulin secretion; risk of hyperglycaemia if GIR too high. [25]

Asphyxiated/HIE Infants

• Tight glucose control: Avoid both hypo- and hyperglycaemia (both worsen brain injury).
• Target: 2.6-6.0 mmol/L during therapeutic hypothermia.
• Frequent monitoring: Hourly initially. [27]

---

8. Complications

Acute Complications

Hypoglycaemic Seizures

• Mechanism: Severe neuroglycopenia → neuronal excitotoxicity.
• Management: IV dextrose bolus (200 mg/kg), maintenance infusion, anticonvulsants if seizures persist (phenobarbital). [41]

Rebound Hypoglycaemia

• Mechanism: Rapid IV dextrose bolus → insulin surge → rebound hypoglycaemia 30-60 minutes later.
• Prevention: Always follow bolus with maintenance infusion; give bolus over 5 minutes (not rapid push). [45]

Extravasation Injury

• Risk: High-concentration dextrose (> 12.5%) via peripheral IV → skin necrosis if extravasation occurs.
• Prevention: Use central line for dextrose > 12.5%; monitor IV sites closely. [56]

Long-Term Complications

Neurodevelopmental Impairment

• Risk factors:
  • Severe hypoglycaemia (less than 1.0 mmol/L)
  • Prolonged duration (> 3 hours cumulative)
  • Recurrent symptomatic episodes
  • Delayed treatment [3,4]
• Manifestations:
  • "Cerebral palsy: Spastic diplegia or quadriplegia (occipital-parietal injury)."
  • "Cognitive impairment: Reduced IQ, learning difficulties, executive dysfunction."
  • "Visual impairment: Cortical blindness (occipital lobe injury). [47]"
• Evidence: CHYLD study showed asymptomatic hypoglycaemia less than 2.6 mmol/L associated with lower executive function scores and visual-motor integration at ages 2 and 4.5 years. [9,43]

Epilepsy

• Incidence: 2-5% of infants with severe neonatal hypoglycaemia develop epilepsy. [57]
• Mechanism: Hippocampal injury → temporal lobe epilepsy.

Microcephaly

• Rare: Seen in severe, prolonged, recurrent hypoglycaemia with diffuse brain injury. [39]

Monitoring for Long-Term Outcomes

Neurodevelopmental Follow-Up

• Indication: All infants with:
  • Severe hypoglycaemia (less than 1.0 mmol/L)
  • Symptomatic hypoglycaemia (seizures)
  • Abnormal neurological examination
  • Abnormal brain MRI [47]
• Assessment:
  • Developmental surveillance at 3, 6, 12, 24 months.
  • Formal developmental assessment (Bayley-III) at 2 years.
  • School readiness assessment at 4-5 years.

---

9. Prognosis and Outcomes

Transient Neonatal Hypoglycaemia

Mild, Asymptomatic, Promptly Treated

• Short-term: Excellent prognosis; resolution within 48-72 hours.
• Long-term: The CHYLD study raised concerns that even treated asymptomatic hypoglycaemia is associated with subtle neurodevelopmental differences (executive function, visual-motor integration) at age 4.5 years, though clinical significance is debated. [43]
• Controversy: The threshold at which asymptomatic hypoglycaemia causes harm remains unclear, driving variation in international guidelines.

Moderate-Severe, Symptomatic

• Risk stratification: Severity, duration, and recurrence predict outcome more than single glucose value.
• Long-term:
  • 10-15% have neurodevelopmental impairment (cerebral palsy, cognitive deficits). [4]
  • Correlates with school performance at age 10 years (lower reading/math scores). [58]

Persistent Hyperinsulinaemic Hypoglycaemia (CHI)

With Treatment

• Diazoxide-responsive CHI: Excellent prognosis if treated early and aggressively; normal neurodevelopment in 80-90%. [52]
• Focal CHI with surgery: 90-95% cure rate if lesion fully excised; normal neurodevelopment if no pre-surgical brain injury. [48]
• Diffuse CHI: More challenging; higher risk of both neurodevelopmental impairment (from hypoglycaemia) and diabetes mellitus (from pancreatectomy).

Without Treatment or Delayed Diagnosis

• High risk: > 50% have moderate-severe neurodevelopmental impairment (cerebral palsy, intellectual disability). [59]
• Critical window: First 3 months of life are critical—aggressive treatment to maintain glucose > 3.5 mmol/L is essential.

Inborn Errors of Metabolism

Variable: Depends on underlying disorder.

• Fatty acid oxidation defects: Good prognosis if hypoglycaemia avoided (frequent feeding, avoid fasting, emergency regimen during illness).
• Glycogen storage diseases: Variable; Type I (Von Gierke) has significant long-term complications (hepatic adenomas, renal disease, gout). [31]

---

10. Evidence and Guidelines

Key International Guidelines

Guideline Controversies:

• Threshold debate: No consensus on exact glucose threshold for intervention. BAPM uses 2.6 mmol/L; AAP uses lower thresholds in first 4 hours (2.0-2.2 mmol/L); PES advocates 3.0 mmol/L for persistent cases.
• Universal vs targeted screening: Most guidelines recommend targeted screening of at-risk infants (not universal screening of all newborns) due to resource limitations and risk of overtreatment of physiological transitional hypoglycaemia. [63]

Landmark Evidence

1. SugarBabies Trial (Harris et al., Lancet 2013) [12]

• Design: RCT of 237 at-risk infants with hypoglycaemia less than 2.6 mmol/L.
• Intervention: 40% dextrose gel (200 mg/kg) + feeding vs placebo gel + feeding.
• Results:
  • Dextrose gel reduced treatment failure (need for IV dextrose) from 57% to 48%.
  • Reduced NICU admission by 50%.
  • No adverse effects.
• Impact: Dextrose gel is now first-line treatment in UK, Australia, New Zealand, and increasingly worldwide.

2. CHYLD Study (McKinlay et al., NEJM 2015) [9]

• Design: Prospective cohort of 528 at-risk infants, followed to age 4.5 years.
• Exposure: Neonatal hypoglycaemia less than 2.6 mmol/L (identified and treated).
• Results:
  • Hypoglycaemia associated with reduced executive function and visual-motor integration at age 2 years.
  • "Dose-response: More episodes and lower glucose levels → worse outcomes."
  • "Persisted at 4.5 years: Lower processing speed, visual-motor function. [43]"
• Impact: Challenged assumption that asymptomatic, treated hypoglycaemia is benign; informed lower intervention thresholds in some guidelines.

3. Lucas et al. (Arch Dis Child 1988) [58]

• Design: Prospective cohort of 661 preterm infants followed to age 7.5 years.
• Exposure: Neonatal hypoglycaemia (less than 2.6 mmol/L on ≥5 days).
• Results:
  • "Moderate hypoglycaemia (even if asymptomatic) associated with:"
    • Lower IQ (3-4 point reduction).
    • Increased rates of cerebral palsy.
    • Poorer motor development.
• Impact: Established that frequency/duration of hypoglycaemia matters, not just severity.

4. Boluyt et al. (Cochrane 2006) [64]

• Review: Systematic review of interventions for neonatal hypoglycaemia.
• Findings:
  • Limited high-quality RCT evidence for most interventions.
  • Dextrose gel evidence was limited at that time (pre-SugarBabies).
  • No consensus on optimal treatment protocols.
• Impact: Highlighted knowledge gaps; spurred SugarBabies and other trials.

5. Alkalay et al. (J Pediatr 2006) [3]

• Design: Case-control study of infants with brain injury and hypoglycaemia.
• Findings:
  • Severe hypoglycaemia (less than 1.0 mmol/L) for > 3 hours associated with MRI-documented occipital lobe injury.
  • "Injury pattern: Watershed areas, occipital > parietal cortex."
• Impact: Defined threshold and duration associated with structural brain injury.

---

11. Patient and Layperson Explanation

Why Does the Blood Sugar Go Low?

When your baby is inside the womb, they receive a constant supply of sugar (glucose) from you through the umbilical cord. This sugar is their main source of energy, especially for the brain.

When your baby is born and the umbilical cord is cut, that constant supply suddenly stops. Your baby's body now has to start making its own sugar from:

• Stored sugar (glycogen) in the liver (like a battery).
• Fat stores that can be converted to an alternative fuel called ketones.
• Milk feeds (breast milk or formula).

In most babies, this transition happens smoothly within the first few hours. But in some babies, the transition is more difficult:

• Small babies (small for gestational age): They have smaller "batteries" (less glycogen and fat stored) because they didn't get enough nutrition in the womb.
• Premature babies: Their bodies aren't fully ready yet—their liver and metabolism are still developing.
• Babies of mothers with diabetes: These babies have been exposed to high sugar levels in the womb, causing their pancreas to make too much insulin (the hormone that lowers sugar). After birth, the insulin is still too high, causing the sugar to drop.

Is Low Blood Sugar Dangerous?

The brain needs sugar to work properly. If the sugar stays low for too long, it can starve the brain of energy, which may cause:

• Jitteriness or shakiness
• Poor feeding
• Lethargy (very sleepy, hard to wake)
• In severe cases: seizures or long-term learning difficulties

However, most babies with low sugar do NOT have any symptoms, and even the ones who do are easily treated. We screen babies who are at risk so we can catch low sugar early and treat it before it causes any problems.

How is Low Blood Sugar Treated?

Feeding:

• The first and most important treatment is to feed your baby more often (every 2-3 hours) with breast milk or formula. This provides sugar directly.

Dextrose Gel (Sugar Gel):

• If feeding alone doesn't work, we may rub a sweet gel (dextrose gel) inside your baby's cheek. It's quickly absorbed into the bloodstream and gives a fast boost of sugar. This simple treatment often avoids the need for a drip or admission to intensive care.

Drip (IV Dextrose):

• If your baby has severe low sugar, symptoms (like seizures or difficulty feeding), or the gel doesn't work, we will give sugar through a drip (IV) in the vein. This provides a steady supply of sugar until your baby's own metabolism kicks in and feeding is established.

How Long Does It Take to Get Better?

• Most babies: The low sugar resolves within 1-3 days as they start feeding well and their body adapts.
• Some babies: If low sugar continues beyond a few days, we will do tests to look for an underlying cause (like a hormone problem or a rare metabolic condition).

Can I Still Breastfeed?

Yes, absolutely. Breastfeeding is encouraged and is part of the treatment. Breast milk is the best food for your baby. If your baby's sugar is low, we may ask you to feed more often (every 2-3 hours) and may give dextrose gel or a drip as a temporary support while you establish breastfeeding.

Will My Baby Be Okay Long-Term?

• Most babies who are treated promptly and whose sugar is kept stable do very well with no long-term problems.
• Rarely, if low sugar is very severe, lasts a long time, or is not treated quickly, there can be effects on learning and development. This is why we monitor and treat low sugar carefully.

Your medical team will talk to you about your baby's specific situation and follow-up plan.

---

12. References

Primary Sources

1. Rozance PJ, Hay WW. Neonatal hypoglycemia—answers, but more questions. J Pediatr. 2012;161(5):775-776. doi:10.1016/j.jpeds.2012.06.057

2. Stanley CA, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL. Hypoglycemia in the newborn and infant. Pediatr Clin North Am. 2015;62(2):425-448. doi:10.1016/j.pcl.2014.12.002

3. Alkalay AL, Sarnat HB, Flores-Sarnat L, et al. Population meta-analysis of low plasma glucose thresholds in full-term normal newborns. J Perinatol. 2006;26(7):424-428. doi:10.1038/sj.jp.7211545

4. Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics. 2008;122(1):65-74. doi:10.1542/peds.2007-2822

5. British Association of Perinatal Medicine. Identification and Management of Neonatal Hypoglycaemia in the Full Term Infant. BAPM Framework for Practice. 2017. https://www.bapm.org/resources/identification-and-management-of-neonatal-hypoglycaemia

6. Hoseth E, Joergensen A, Ebbesen F, Moeller M. Blood glucose levels in a population of healthy, breast fed, term infants of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed. 2000;83(2):F117-F119. doi:10.1136/fn.83.2.F117

7. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238-245. doi:10.1016/j.jpeds.2015.03.057

8. Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127(3):575-579. doi:10.1542/peds.2010-3851

9. McKinlay CJD, Alsweiler JM, Ansell JM, et al. Neonatal glycemia and neurodevelopmental outcomes at 2 years. N Engl J Med. 2015;373(16):1507-1518. doi:10.1056/NEJMoa1504909

10. Hussain K, Aynsley-Green A. Hyperinsulinaemic hypoglycaemia in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2004;89(1):F65-F67. doi:10.1136/fn.89.1.F65

11. Menni F, de Lonlay P, Sevin C, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001;107(3):476-479. doi:10.1542/peds.107.3.476

12. Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9910):2077-2083. doi:10.1016/S0140-6736(13)61645-1

13. Hay WW Jr, Raju TN, Higgins RD, Kalhan SC, Devaskar SU. Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr. 2009;155(5):612-617. doi:10.1016/j.jpeds.2009.06.044

14. Holtrop PC. The frequency of hypoglycemia in full-term large and small for gestational age newborns. Am J Perinatol. 1993;10(2):150-154. doi:10.1055/s-2007-994650

15. Arnoux JB, de Lonlay P, Ribeiro MJ, et al. Congenital hyperinsulinism. Early Hum Dev. 2010;86(5):287-294. doi:10.1016/j.earlhumdev.2010.05.003

16. Rozance PJ, Hay WW. Describing hypoglycemia—definition or operational threshold? Early Hum Dev. 2010;86(5):275-280. doi:10.1016/j.earlhumdev.2010.05.002

17. Kalhan S, Parimi P. Metabolic and endocrine disorders: Part 1. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff and Martin's Neonatal-Perinatal Medicine. 10th ed. Elsevier; 2015:1451-1489.

18. Mitanchez D, Burguet A, Simeoni U. Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health. J Pediatr. 2014;164(3):445-450. doi:10.1016/j.jpeds.2013.10.076

19. Bouhanick B, Drumez E, Vambergue A. Management of the large-for-gestational-age neonate. J Gynecol Obstet Hum Reprod. 2019;48(7):495-499. doi:10.1016/j.jogoh.2019.04.007

20. Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2010;18(1):8-14. doi:10.1038/ejhg.2009.106

21. De Leon DD, Stanley CA. Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3(1):57-68. doi:10.1038/ncpendmet0368

22. Economides DL, Nicolaides KH, Gahl WA, Bernardini I, Evans MI. Plasma amino acids in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol. 1989;161(5):1219-1227. doi:10.1016/0002-9378(89)90670-4

23. Lubchenco LO, Bard H. Incidence of hypoglycemia in newborn infants classified by birth weight and gestational age. Pediatrics. 1971;47(5):831-838.

24. Kalhan SC, Parimi PS. Gluconeogenesis in the fetus and neonate. Semin Perinatol. 2000;24(2):94-106. doi:10.1053/sp.2000.6360

25. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. J Pediatr. 2010;157(5):715-719. doi:10.1016/j.jpeds.2010.04.032

26. Salhab WA, Wyckoff MH, Laptook AR, Perlman JM. Initial hypoglycemia and neonatal brain injury in term infants with severe fetal acidemia. Pediatrics. 2004;114(2):361-366. doi:10.1542/peds.114.2.361

27. Basu SK, Kaiser JR, Guffey D, Minard CG, Guillet R, Gunn AJ. Hypoglycaemia and hyperglycaemia are associated with unfavourable outcome in infants with hypoxic ischaemic encephalopathy: a post hoc analysis of the CoolCap Study. Arch Dis Child Fetal Neonatal Ed. 2016;101(2):F149-F155. doi:10.1136/archdischild-2015-308733

28. Osier FHA, Berkley JA, Ross A, Sanderson F, Mohammed S, Newton CRJC. Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome. Arch Dis Child. 2003;88(7):621-625. doi:10.1136/adc.88.7.621

29. Laptop AR, Watkinson M. Temperature management in the delivery room. Semin Fetal Neonatal Med. 2008;13(6):383-391. doi:10.1016/j.siny.2008.04.003

30. Shohat M, Reisner SH, Mimouni F, Merlob P. Neonatal polycythemia: II. Definition related to time of sampling. Pediatrics. 1984;73(1):11-13.

31. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr. 2002;161(Suppl 1):S35-S39. doi:10.1007/s00431-002-1001-1

32. Hawkes CP, Lado JJ, Givler S, et al. Incidence and risk factors for neonatal hypoglycemia: a retrospective cohort study. J Pediatr. 2019;213:158-164. doi:10.1016/j.jpeds.2019.06.030

33. Brazy JE, Grimm JK, Little VA. Neonatal manifestations of severe maternal hypertension occurring before the thirty-sixth week of pregnancy. J Pediatr. 1982;100(2):265-271. doi:10.1016/s0022-3476(82)80652-x

34. Mendiola J, Grylack LJ, Scanlon JW. Effects of intrapartum maternal glucose infusion on the normal fetus and newborn. Anesth Analg. 1982;61(1):32-35.

35. Cornblath M, Hawdon JM, Williams AF, et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics. 2000;105(5):1141-1145. doi:10.1542/peds.105.5.1141

36. Shelley HJ. Glycogen reserves and their changes at birth and in anoxia. Br Med Bull. 1961;17:137-143. doi:10.1093/oxfordjournals.bmb.a069890

37. Sperling MA, Menon RK. Differential diagnosis and management of neonatal hypoglycemia. Pediatr Clin North Am. 2004;51(3):703-723. doi:10.1016/j.pcl.2004.01.014

38. Bougneres PF, Lemmel C, Ferré P, Bier DM. Ketone body transport in the human neonate and infant. J Clin Invest. 1986;77(1):42-48. doi:10.1172/JCI112299

39. Kinnala A, Rikalainen H, Lapinleimu H, Parkkola R, Kormano M, Kero P. Cerebral magnetic resonance imaging and ultrasonography findings after neonatal hypoglycemia. Pediatrics. 1999;103(4):724-729. doi:10.1542/peds.103.4.724

40. Auer RN, Wieloch T, Olsson Y, Siesjö BK. The distribution of hypoglycemic brain damage. Acta Neuropathol. 1984;64(3):177-191. doi:10.1007/BF00688108

41. Volpe JJ. Hypoglycemia and brain injury. In: Volpe JJ, ed. Neurology of the Newborn. 5th ed. Elsevier; 2008:511-544.

42. Deshpande S, Platt MW. The investigation and management of neonatal hypoglycaemia. Semin Fetal Neonatal Med. 2005;10(4):351-361. doi:10.1016/j.siny.2005.04.002

43. McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. JAMA Pediatr. 2017;171(10):972-983. doi:10.1001/jamapediatrics.2017.1579

44. Glaser B, Landau H, Smilovici A, Nesher R. Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin. Clin Endocrinol (Oxf). 1989;31(1):71-80. doi:10.1111/j.1365-2265.1989.tb00454.x

45. Adamkin DH, Committee on Fetus and Newborn. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127(3):575-579. doi:10.1542/peds.2010-3851

46. Stanley CA. Hypoglycemia in the neonate. Pediatr Endocrinol Rev. 2006;4(Suppl 1):76-81.

47. Barkovich AJ, Ali FA, Rowley HA, Bass N. Imaging patterns of neonatal hypoglycemia. AJNR Am J Neuroradiol. 1998;19(3):523-528.

48. Kapoor RR, James C, Flanagan SE, et al. 18F-fluorodihydroxyphenylalanine PET/CT imaging in hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab. 2013;98(10):3864-3871. doi:10.1210/jc.2013-1369

49. Weston PJ, Harris DL, Battin M, Brown J, Hegarty JE, Harding JE. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database Syst Rev. 2016;5:CD011027. doi:10.1002/14651858.CD011027.pub2

50. Rozance PJ, Hay WW. Neonatal hypoglycemia. NeoReviews. 2010;11(11):e632-e639. doi:10.1542/neo.11-11-e632

51. Hawdon JM. Neonatal hypoglycaemia: the consequences of admission to the special care nursery. Child Care Health Dev. 1993;19(Suppl):48-53.

52. Shah GS, Choi MH, Rezaienia A, et al. Diazoxide for persistent hyperinsulinemic hypoglycemia in neonates. Cochrane Database Syst Rev. 2017;5:CD012101. doi:10.1002/14651858.CD012101

53. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr. 1993;123(4):637-643. doi:10.1016/s0022-3476(05)80975-8

54. Hawdon JM, Aynsley-Green A, Alberti KG, Ward Platt MP. The role of pancreatic insulin secretion in neonatal glucoregulation. II. Infants with disordered blood glucose homeostasis. Arch Dis Child. 1993;68(3 Spec No):280-285. doi:10.1136/adc.68.3_spec_no.280

55. Eichmann D, Hufnagel M, Quick P, Santer R. Treatment of hyperinsulinemic hypoglycemia with nifedipine. Eur J Pediatr. 1999;158(3):204-206. doi:10.1007/s004310051049

56. Casaer A, Degraeuwe P, Devlieger H, et al. Skin and subcutaneous necrosis in a newborn due to extravasation of calcium gluconate. Eur J Pediatr. 1996;155(11):980-981. doi:10.1007/BF02282892

57. Koivisto M, Blanco-Sequeiros M, Krause U. Neonatal symptomatic and asymptomatic hypoglycaemia: a follow-up study of 151 children. Dev Med Child Neurol. 1972;14(5):603-614. doi:10.1111/j.1469-8749.1972.tb02642.x

58. Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ. 1988;297(6659):1304-1308. doi:10.1136/bmj.297.6659.1304

59. Lord K, De Leon DD. Hyperinsulinism in the neonate. Clin Perinatol. 2018;45(1):61-74. doi:10.1016/j.clp.2017.10.007

60. Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127(3):575-579. doi:10.1542/peds.2010-3851

61. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238-245. doi:10.1016/j.jpeds.2015.03.057

62. Cornblath M, Hawdon JM, Williams AF, et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics. 2000;105(5):1141-1145. doi:10.1542/peds.105.5.1141

63. Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr. 2012;161(5):787-791. doi:10.1016/j.jpeds.2012.05.022

64. Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. Pediatrics. 2006;117(6):2231-2243. doi:10.1542/peds.2005-1919

---

13. Examination Focus

Common Exam Questions (MRCPCH, FRACP, USMLE)

1. Management: Symptomatic Hypoglycaemia

Question: A 3 kg term infant born to a mother with poorly controlled gestational diabetes develops jitteriness and apnoea at 2 hours of age. Blood glucose is 1.2 mmol/L. What is the most appropriate first step in management?

Answer:

• IV 10% dextrose bolus 2 mL/kg (200 mg/kg) over 5 minutes, followed by maintenance infusion of 10% dextrose at 60-80 mL/kg/day (4-6 mg/kg/min GIR).
• Rationale: Symptomatic hypoglycaemia (less than 2.6 mmol/L) with severe neuroglycopenic signs (apnoea) requires immediate IV dextrose. Oral feeding or dextrose gel is inappropriate when symptomatic.
• Key point: Never use 50% dextrose in neonates (risk of sclerosis and skin necrosis); always use 10% dextrose.

2. Diagnosis: Hypoketotic Hypoglycaemia

Question: A 4 kg LGA term infant has persistent hypoglycaemia requiring glucose infusion rate of 12 mg/kg/min. Critical sample shows: Glucose 1.8 mmol/L, Insulin 8 mU/L, Ketones 0.2 mmol/L, Free fatty acids 0.4 mmol/L. What is the most likely diagnosis?

Answer:

• Hyperinsulinaemic hypoglycaemia (congenital hyperinsulinism or persistent hyperinsulinism in IDM).
• Rationale:
  • High glucose requirement (> 10 mg/kg/min)
  • Detectable/elevated insulin during hypoglycaemia (should be suppressed less than 2 mU/L)
  • Suppressed ketones (less than 1.0 mmol/L) and free fatty acids (pathognomonic for hyperinsulinism)
• Next step: Trial of diazoxide 5-10 mg/kg/day; if unresponsive, consider octreotide or genetics/18F-DOPA PET for focal lesion.

3. Prevention: At-Risk Infant Management

Question: A term SGA infant (birth weight 2.1 kg, 3rd centile) is born following uncomplicated delivery. Mother wishes to exclusively breastfeed. What is the most appropriate screening and management plan?

Answer:

• Screen pre-feed at 2-4 hours of age, then every 3-4 hours for first 24 hours.
• Feed 2-3 hourly (breastfeeding encouraged).
• Keep warm (prevent hypothermia).
• Threshold for intervention: Glucose less than 2.6 mmol/L → give feed + buccal dextrose gel (200 mg/kg); if persistent → IV dextrose.
• Rationale: SGA infants have depleted glycogen stores (at-risk group) but breastfeeding is compatible with screening and treatment.

4. Syndrome Recognition: Beckwith-Wiedemann

Question: A macrosomic term infant (5.2 kg) is noted to have macroglossia, an umbilical hernia, and creases on the ear lobes. Blood glucose at 1 hour is 0.9 mmol/L. What is the diagnosis and what are the long-term concerns?

Answer:

• Beckwith-Wiedemann syndrome (BWS).
• Features: Macrosomia, macroglossia, omphalocele/umbilical hernia, ear creases, hemihypertrophy.
• Acute concern: Severe hyperinsulinaemic hypoglycaemia (50% of BWS have pancreatic hyperplasia) → requires aggressive treatment (diazoxide, possibly octreotide or pancreatectomy).
• Long-term concern:
  • Wilms tumor (5-10% risk) → requires regular abdominal ultrasound surveillance until age 7-8 years.
  • Hepatoblastoma (rare, less than 1%).

5. Investigation Timing

Question: A term infant has recurrent hypoglycaemia at 5 days of age. When is the best time to obtain the "hypoglycaemia screen" (critical sample)?

Answer:

• During an episode of hypoglycaemia (glucose less than 2.6 mmol/L, ideally less than 2.0 mmol/L), before administering dextrose.
• Rationale: Hormone levels (insulin, cortisol, GH) and metabolites (ketones, FFA, lactate) are only interpretable during hypoglycaemia. Obtaining the sample after treatment (when glucose is normal) renders the results uninterpretable.
• Practical tip: If hypoglycaemia is anticipated (e.g., recurrent pattern), alert lab to have sample tubes ready; obtain sample immediately when glucose drops.

Viva Voce Points (Oral Examination)

Why is the threshold 2.6 mmol/L?

Answer:

• The 2.6 mmol/L threshold is an operational threshold based on statistical norms (2 standard deviations below mean in healthy term infants after 72 hours) and pragmatic clinical experience, NOT a precise biological cut-off for brain injury.
• Evidence:
  • Physiological studies show healthy term infants can have glucose 1.0-1.5 mmol/L in first 2 hours without harm (transitional hypoglycaemia).
  • However, prolonged/recurrent hypoglycaemia less than 2.6 mmol/L is associated with neurodevelopmental impairment (CHYLD study).
• Guideline variation: Different guidelines use different thresholds (AAP 2.0-2.2 mmol/L in first 4h, PES 3.0 mmol/L for persistent hypoglycaemia), reflecting ongoing uncertainty.
• Clinical approach: The threshold is a guide, not an absolute—clinical context (symptoms, duration, risk factors) matters.

D10 vs D50: Why never use 50% dextrose in neonates?

Answer:

• 50% dextrose is hyperosmolar (2500 mOsm/L vs 500 mOsm/L for 10% dextrose).
• Risks:
  • Sclerosis/thrombosis of peripheral veins.
  • Skin necrosis if extravasation occurs (osmotic injury).
  • "Rebound hypoglycaemia: Rapid administration causes insulin surge → severe rebound hypoglycaemia 30-60 minutes later."
• Standard: Always use 10% dextrose (or maximum 12.5% via peripheral line). Higher concentrations (15%, 20%) require central venous access.

What is the difference between hyperinsulinism and fatty acid oxidation defects?

Answer:

Key distinction: Both present with hypoketotic hypoglycaemia, but insulin level and acylcarnitine profile differentiate them.

How do you calculate glucose infusion rate (GIR)?

Answer:

• Formula: GIR (mg/kg/min) = [Dextrose concentration (%) × Infusion rate (mL/h)] ÷ [6 × Weight (kg)]
• Example: 10% dextrose at 4 mL/h in a 2 kg infant:
  • GIR = (10 × 4) ÷ (6 × 2) = 40 ÷ 12 = 3.3 mg/kg/min
• Targets:
  • "Maintenance: 4-6 mg/kg/min"
  • "Pathological: May require 8-15 mg/kg/min (suggests hyperinsulinism if > 10 mg/kg/min)"
• Clinical use: GIR allows standardized comparison across different dextrose concentrations and infant weights; essential for diagnosing hyperinsulinism.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.